Antitumor Activity of Rapamycin in Patients with Recurrent PTEN-Deficient Glioblastoma
Author Information
Author(s): Tim F. Cloughesy, Koji Yoshimoto, Phioanh Nghiemphu, Kevin Brown, Julie Dang, Shaojun Zhu, Teli Hsueh, Yinan Chen, Wei Wang, David Youngkin, Linda Liau, Neil Martin, Don Becker, Marvin Bergsneider, Albert Lai, Richard Green, Tom Oglesby, Michael Koleto, Jeff Trent, Steve Horvath, Paul S. Mischel, Ingo K. Mellinghoff, Charles L. Sawyers
Primary Institution: University of California Los Angeles
Hypothesis
Can rapamycin effectively inhibit tumor growth in patients with recurrent glioblastoma that lacks PTEN expression?
Conclusion
Rapamycin shows anticancer activity in PTEN-deficient glioblastoma and should be studied further, potentially in combination with other therapies.
Supporting Evidence
- Seven out of 14 patients showed a significant reduction in tumor cell proliferation after treatment.
- Intratumoral rapamycin concentrations were sufficient to inhibit mTOR in all patients.
- Activation of Akt was observed in some patients, which correlated with shorter time-to-progression.
Takeaway
This study tested a drug called rapamycin on patients with a type of brain cancer that has a specific genetic change. It found that the drug can help slow down the cancer's growth in some patients.
Methodology
Patients received daily oral rapamycin for about a week before surgery, and tumor samples were analyzed for mTOR activity and cell proliferation.
Potential Biases
Potential selection bias due to the specific inclusion criteria for PTEN-deficient tumors.
Limitations
The study had a small sample size and focused only on patients with PTEN-deficient tumors.
Participant Demographics
All participants were adults with recurrent glioblastoma and evidence of PTEN loss.
Statistical Information
P-Value
0.0047
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website